Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ERBB3 V104L |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor HER3 Inhibitor Pertuzumab Trastuzumab |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ERBB3 V104L | gastric adenocarcinoma | predicted - sensitive | HER2 Inhibitor | Irinotecan + Pyrotinib | Case Reports/Case Series | Actionable | In a clinical case study, combination treatment Camptosar (irinotecan) and Pyrotinib in a patient with metastatic gastric adenocarcinoma harboring ERBB3 V104L, who had relapsed on prior treatment with chemotherapy, led to stable disease and a progression-free survival of 7.6 months (PMID: 33500629). | 33500629 |
| ERBB3 V104L | breast cancer | sensitive | Patritumab deruxtecan | Preclinical - Cell culture | Actionable | In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line expressing ERBB3 (HER3) V104L in culture (PMID: 35503762). | 35503762 | |
| ERBB3 V104L | Her2-receptor positive breast cancer | sensitive | HER2 Inhibitor | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) treatment inhibited activation of Erbb2 (Her2) and decreased viability and proliferation in an ERBB2 (HER2)-positive breast cancer cell line expressing ERBB3 (HER3) V104L in culture (PMID: 38751013). | 38751013 |
| ERBB3 V104L | Her2-receptor positive breast cancer | sensitive | HER2 Inhibitor | Tucatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tukysa (tucatinib) treatment inhibited activation of Erbb2 (Her2) and decreased viability and proliferation in an ERBB2 (HER2)-positive breast cancer cell line expressing ERBB3 (HER3) V104L in culture (PMID: 38751013). | 38751013 |
| ERBB3 V104L | Her2-receptor positive breast cancer | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) treatment inhibited activation of Erbb2 (Her2) and decreased viability and proliferation in an ERBB2 (HER2)-positive breast cancer cell line expressing ERBB3 (HER3) V104L in culture (PMID: 38751013). | 38751013 |